Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 in advanced or metastatic biliary tract cancer
NCT03833661Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in biliary tract cancer (BTC), sponsored by EMD Serono. Primary endpoint: Objective Response Rate up to 555 days. Started Mar 2019; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03833661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833661.